JULIE SARGENT

Working within the CardioMetabolic Business Unit

Responsible for engaging Endocrinologists & Cardiologists, and other KOL's to promote Multaq (dronedarone) and Toujeo Max (insulin glargine)

ReLaunched Multaq(dronedarone) to Cardiologists

Rank (April 2024): 8/95, 101.5% goal

Promoted Toujeo Max to Endocrinologists (Insulin glargine)

Rank (April 2024): 7/95, 124.7% goal

Combined Attainment Ranking; 6 (33 prior to start)

Weekly collaboration with MSL's and Agile Coaches for OKR tactics

Winlevi (clascoterone) Launch, November 2021- Present

Winlevi National Rank 2021: 3/100

Winlevi National Rank 2022: 12/100

Winlevi 'Big Kahuna' Contest Top 20 November 2022: 13/100

'Elevate' & Grow Top 20 contest: Current 2023

Re-Launch of Steroid Portfolio Brand Formulation: June 2020: Ultravate, Halog

Steroid Portfolio Ranking: 3/100, 143% over goal attainment, December 2021

Absorica LD Launch, June 2020: Activated Pittsburgh market to goal status with 15 rxs per quarter

Promoted to Fit Team Member for Best Practices & Field intelligence, 2021-Present

Specialty Pharmacy Collaborations & expertise in reimbursement and managed care to secure Portfolio Brands first line

Conducted pharmaceutical annual, random and closeout sample inventories/audits for multiple pharmaceutical companies and their representatives

Worked on various pharmaceutical contracts to conduct product recalls, audits and inventory counts within hospital, medical office and surgical settings

Performed site/facility inspections to align with pharmaceutical compliance requirements

Sunovion Respiratory 6 month Contract: Responsible for launch of Utibron Neohaler (indacaterol/glycopyrrolate) and Seebri Neohaler (glycopyrrolate)

National Portfolio Rank: 19/100

Developed client accounts and grew market volume within COPD market calling on Allergists, Otolaryngologists, respiratory therapists and high volume primary care physicians

Astrazeneca Respiratory 6 month contract:

Increased voice and support for Symbicort (budesonide/formoterol)and Bevespi Aerosphere (glycopyrrolate formoterol)

Educated providers and respiratory therapists on importance of key features and benefits of products for quality of life measures

Networked with area medical practices and providers to introduce practice services and patient care

Promoted and generated office referrals through sales calls and field intelligence

Worked as Patient Liaison for continued care amongst chronic pain candidates

Re-Launched Ranbaxy's Dermatology Portfolio formulations: Kenalog Spray (triamcinolone acetonide), Ultravate (halobetasol proprionate) , Halog (halcinonide) formulations to Dermatologists into first-line status 1st quarter

National Steroid Portfolio Rank: 2/64 , 2011

District Dermatology Trainer: 2010-2012

Territory Copay Redemption Lead: 2011

Launched Obagi's first and only prescription acne product: Soluclenz (solubilized benzoyl peroxide) to Dermatologists within the tri-state market arena

Ranked: 8/74, 2009

Recruited to Regional Market Access Lead/Step Therapy Pull through

Launched Cardiovascular Portfolio: Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) to Cardiologists, Endocrinologists and high volume primary care physicians within office and hospital settings

Awarded "Statin Star" for early adoption success of 127% over goal for Zetia, 2003

Exceeded Zetia Goal attainment over 100%: 2004 - 2007

Post launch success of Vytorin: 134,2005

Statin Portfolio District Top Ten Recipient: 2005

Launched Clarinex to allergists, pulmonologists, high volume primary care physicians and pediatricians

Converted Claritin loyalists to Clarinex early adopters

Relaunched Schering's Dermatology portfolio formulations: Diprolene (betamethasone dipropionate), Elocon (mometasone furoate)

National Steroid Portfolio Rank: 2/68

Leadership Program Candidate: 2001-2002

Dermatology District Sales Trainer: 1999-2002

National Monthly Dermatology Top Ten: 1998-2002

POA Dermatology Presenter: 1999-2001

Nominated to attend all National Dermatology AAD Conferences